XNW3009 PhII Clinical Trial First Patient In
XNW 3009 is one of the new generation of selective hURAT1 inhibitors.
Evopoint has enrolled the first patient in phase II clinical trial on April 7, 2021. This clinical trial was conducted by Professor Li Zhanguo and Professor Zhang Xuewu in Peking University People's Hospital and other nearly 30 hospitals and centers at the same time in China.
